IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth

Anticancer Research

Volumn 28, Issue 3 A, 2008, Pages 1509-1516

  Coulter, Don W ^a   Blatt, Julie ^a   D'Ercole, A Joseph ^a   Moats Staats, Billie M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

IGF I receptor; mTOR; MYC N; Neuroblastoma; Rapamycin; Temsirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHAIR3; MYC PROTEIN; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; NEUROBLASTOMA; PROTEIN KINASES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 45949109906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pizzo PA and Poplack DG: Principles and Practice of Pediatric Oncology. Lippincott William and Wilkins, Philadelphia PA. Fourth Edition, pp. 895-904, 2002.
2. Yeazel MW, Ross JA, Buckley JD, Woods WG, Ruccione K and Robison LL: High birth weight and risk of specific childhood cancers: a report from the Children's Cancer Group. J Pediatr 131(5): 671-677, 1997.
3. Martin DM, Yee D, Carlson RO and Feldman EL: Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines. Mol Brain Res 15: 241-246, 1992.
4. Misawa A, Hosoi H, Arimoto A, Shikata T, Akioka S, Matsumura T, Houghton PJ and Sawada T: MYC-N induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 60(1): 64-69, 2000.
5. Kurmasheva RT and Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766(1): 1-22, 2006.
6. Cohick WS and Clemmons DR: The insulin-like growth factors. Annu Rev Physiol 55: 131-153, 1993.
7. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR - targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
8. Rowinsky EK: Targeting the molecular target of Rapamycin (mTOR). Curr Opin Oncol 16(6): 564-565, 2004.
9. Wan X, Mendoza A, Khanna C and Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65(6): 2406-2411, 2005.
10. Crespo JL and Hall MN: Elucidating TOR signaling and Rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev 66(4): 579-591, 2002.
11. Gera J, Mellinghoff IK, Shi Y, Rettig M, Tran C, Hsu J-H, Sawyers CL and Lichtenstein A: AKT activity determines sensitivity to mammalian target of Rapamycin (mTOR) inhibitors by regulating cyclin Dl and c-myc expression. J Biol Chem 279: 2737-2746, 2004.
12. Faivre S, Kroemer G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discovery 5(8): 671-688, 2006.
13. Hartford CM and Ratain MJ: Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol and Ther 82: 381-388, 2007.
14. Schubert M, Venkataramanan R, Holt DW, Shaw LM, McGhee W, Reyes J, Webber S and Sindhi R: Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transpl 4: 767-773, 2004.
15. Iman DS and Shay JW: Modification of myc gene amplification in human somatic cell hybrids. Cancer Res 49: 4417-4422, 1989.
16. Grandinetti KB, Spengler BA, Biedler JL and Ross RA: Loss of one HuD allele on chromosome #1p selects for amplification of the MYC-N proto-oncogene in human neuroblastoma cells. Oncogene 25: 706-712, 2006.
17. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1): 156-159, 1987.
18. Frohman M, Dush M and Martin G: Rapid production of fulllength cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Pro Nat Acad Sci USA 85(23): 8998-9002, 1988.
19. Retsch-Bogart G, Stiles AD, Moats-Staats BM, Van Scott MR, Boucher RC and D'Ercole AJ: Canine tracheal epithelial cells express the type 1 insulin-like growth factor receptor and proliferate in response to insulin-like growth factor 1. Am J Respir Cell Mol Biol 3: 227-234, 1990.
20. Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nature Protocol 1(3): 1458-1461, 2006.
21. El-Badry OM et al: Insulin like growth factor II mediated proliferation of human neuroblastoma. J Clin Invest 87(2): 648-657, 1991.
22. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ and Cuatrecasas P: Monoclonal antibodies to receptors for insulin and somatomedin C. J Biol Chem 258(10): 6561-6566, 1983.
23. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGFlR-dependent mechanism. Oncogene 26: 1932-1940, 2007.